
Dr. M’s SPA Newsletter Volume 15 Issue 13
Literature Review 1) An exciting phase three trial with the CETP inhibitor Obicetrapib has shown serious promise for ASCVD and Alzheimer’s Disease (AD). “In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in … Continue reading → The post Dr. M’s SPA Newsletter Volume 15 Issue 13 appeared…